Abstract
The outbreak of SARs-CoV-2 with emerging new variants is leading to global health crisis and has brought a major concern for patients with comorbidities. Parkinson’s disease (PD) is a motor neurodegenerative disease involving various metabolic and psychological ailments along with the common occurrence of hyposmia as observed in COVID-19 patients. In addition, the observed surplus inflammatory responses in both diseases are also alarming. Alongside, angiotensin-converting enzyme 2 (ACE2) receptor, essentially required by SARS-CoV-2 to enter the cell and dopamine decarboxylase (DDC), required for dopamine synthesis is known to co-regulate in the non-neuronal cells. Taken together, these conditions suggested the probable reciprocal pathological relation between COVID-19 and PD and also suggested that during comorbidities, the disease diagnosis and therapeutics are critical and may engender severe health complications. In this review, we discuss various events and mechanisms which may have implications for the exacerbation of PD conditions and must be taken into account during the treatment of patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Availability of Data and Material
Not applicable.
References
Abreu GEA, Aguilar MEH, Covarrubias DH, Durán FR (2020) Amantadine as a drug to mitigate the effects of COVID-19. Med Hypotheses. https://doi.org/10.1016/j.mehy.2020.109755
Ait Wahmane S, Achbani A, Ouhaz Z et al (2020) The possible protective role of α-synuclein against severe acute respiratory syndrome coronavirus 2 infections in patients with Parkinson’s disease. Mov Disord 35:1293–1294. https://doi.org/10.1002/MDS.28185
Alavi Darazam I, Hatami F, Rabiei MM et al (2020) An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: a structured summary of a study protocol for a randomized controlled l trial. Trials 21
Anwar F, Naqvi S, Al-Abbasi FA et al (2020) Targeting COVID-19 in Parkinson’s patients: drugs repurposed. Curr Med Chem. https://doi.org/10.2174/0929867327666200903115138
Aranda-Abreu GE, Aranda-Martínez JD, Araújo R (2021) Use of amantadine in a patient with SARS-CoV-2. J Med Virol 93:110–111
Araújo R, Aranda-Martínez JD, Aranda-Abreu GE (2020) Amantadine treatment for people with COVID-19. Arch Med Res 51:739–740. https://doi.org/10.1016/j.arcmed.2020.06.009
Artusi CA, Romagnolo A, Ledda C et al (2021) COVID-19 and Parkinson’s disease: what do we know so far? J Parkinsons Dis 11:445–454
Baba Y, Kuroiwa A, Uitti RJ et al (2005) Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord 11:493–498. https://doi.org/10.1016/J.PARKRELDIS.2005.07.005
Baig AM, Khaleeq A, Syeda H (2020) Docking prediction of amantadine in the receptor binding domain of spike protein of SARS-CoV-2. ACS Pharmacol Transl Sci 3:1430–1433. https://doi.org/10.1021/acsptsci.0c00172
Barcia C (2013) Glial-Mediated Inflammation Underlying Parkinsonism. Scientifica 20131–15. https://doi.org/10.1155/2013/357805
Basova L, Najera JA, Bortell N et al (2018) Dopamine and its receptors play a role in the modulation of CCR5 expression in innate immune cells following exposure to Methamphetamine: Implications to HIV infection. PLoS ONE. https://doi.org/10.1371/journal.pone.0199861
Bohnen NI, Müller MLTM, Kotagal V et al (2010) Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease. Brain 133:1747–1754. https://doi.org/10.1093/brain/awq079
Bondy B (2002) Pathophysiology of depression and mechanisms of treatment. Dialogues Clin Neurosci 4:7–20. https://doi.org/10.31887/DCNS.2002.4.1/BBONDY
Braak H, del Tredici K (2009) Prologue. Adv Anat Embryol Cell Biol 201:1–8. https://doi.org/10.1007/978-3-540-79850-7_1
Brown LK (1994) Respiratory dysfunction in Parkinson’s disease. Clin Chest Med 15:715–727
Burn DJ (2002) Beyond the iron mask: towards better recognition and treatment of depression associated with Parkinson’s disease. Mov Disord 17:445–454. https://doi.org/10.1002/MDS.10114
Cardoso SRX, Pereira JS (2002) Analysis of breathing function in Parkinson’s disease. Arq Neuropsiquiatr 60:91–95. https://doi.org/10.1590/S0004-282X2002000100016
Carey RM, Lee RJ (2019) Taste receptors in upper airway innate immunity. Nutrients 11
Cartella SM, Terranova C, Rizzo V et al (2021) COVID-19 and Parkinson’s disease: an overview. J Neurol 268:4415–4421. https://doi.org/10.1007/S00415-021-10721-4
Chalif JI, Sitsapesan HA, Pattinson KTS et al (2014) Dyspnea as a side effect of subthalamic nucleus deep brain stimulation for Parkinson’s disease. Respir Physiol Neurobiol 192:128–133. https://doi.org/10.1016/J.RESP.2013.12.014
Checconi P, de Angelis M, Marcocci ME et al (2020) Redox-modulating agents in the treatment of viral infections. Int J Mol Sci 21:1–21. https://doi.org/10.3390/IJMS21114084
Chen ZF, Shi SM, Hu RX et al (2003) Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60:1059–1065. https://doi.org/10.1001/ARCHNEUR.60.8.1059
Cilia R, Bonvegna S, Straccia G et al (2020) Effects of COVID-19 on Parkinson’s disease clinical features: a community-based case-control study. Mov Disord 35:1287–1292. https://doi.org/10.1002/MDS.28170
Cohen ME, Eichel R, Steiner-Birmanns B et al (2020) A case of probable Parkinson’s disease after SARS-CoV-2 infection. Lancet Neurol 19:804–805. https://doi.org/10.1016/S1474-4422(20)30305-7
Cortés-Borra A, Aranda-Abreu GE (2021) Amantadine in the prevention of clinical symptoms caused by SARS-CoV-2. Pharmacol Rep. https://doi.org/10.1007/s43440-021-00231-5
Cossu G, Melis M, Sarchioto M et al (2018) 6-n-propylthiouracil taste disruption and TAS2R38 nontasting form in Parkinson’s disease. Mov Disord 33:1331–1339. https://doi.org/10.1002/mds.27391
Dandekar A, Mendez R, Zhang K (2015) Cross talk between ER stress, oxidative stress, and inflammation in health and disease. Methods Mol Biol 1292:205–214. https://doi.org/10.1007/978-1-4939-2522-3_15
D’Arrigo A, Floro S, Bartesaghi F et al (2020) Respiratory dysfunction in Parkinson’s disease: a narrative review. ERJ Open Research 6:00165–02020. https://doi.org/10.1183/23120541.00165-2020
Doty RL, Hawkes CH (2019) Chemosensory dysfunction in neurodegenerative diseases. In: Handbook of Clinical Neurology. Elsevier B.V., pp 325–360
Egan SJ, Laidlaw K, Starkstein S (2015) Cognitive behaviour therapy for depression and anxiety in Parkinson’s disease. J Parkinsons Dis 5:443–451
Ejlerskov P, Hultberg JG, Wang JY et al (2015) Lack of neuronal IFN-β-IFNAR causes lewy body- and Parkinson’s disease-like dementia. Cell 163:324–339. https://doi.org/10.1016/J.CELL.2015.08.069
Escobales N, Nuñez RE, Javadov S (2019) Mitochondrial angiotensin receptors and cardioprotective pathways. Am J Physiol Heart Circ Physiol 316:H1426–H1438
Espay AJ, Vizcarra JA, Marsili L et al (2019) Revisiting protein aggregation as pathogenic in sporadic Parkinson and Alzheimer diseases. Neurology 92:329–337. https://doi.org/10.1212/WNL.0000000000006926
Estenne M, Hubert M, de Troyer A (1984) Respiratory-muscle involvement in Parkinson’s disease. N Engl J Med 311:1516–1517. https://doi.org/10.1056/NEJM198412063112314
Fasano A, Antonini A, Katzenschlager R et al (2020) Management of advanced therapies in Parkinson’s disease patients in times of humanitarian crisis: the COVID-19 experience. Mov Disord Clin Pract 7:361–372. https://doi.org/10.1002/MDC3.12965
Fazzini E, Fleming J, Fahn S (1992) Cerebrospinal fluid antibodies to coronavirus in patients with Parkinson’s disease. Mov Disord 7:153–158. https://doi.org/10.1002/MDS.870070210
Filograna R, Beltramini M, Bubacco L, Bisaglia M (2016) Anti-oxidants in Parkinson’s disease therapy: a critical point of view. Curr Neuropharmacol 14:260–271. https://doi.org/10.2174/1570159X13666151030102718
Fink K, Nitsche A, Neumann M et al (2021) Amantadine inhibits SARS-CoV-2 in vitro. Viruses. https://doi.org/10.3390/v13040539
Finkel Y, Mizrahi O, Nachshon A, Weingarten-Gabbay S, Morgenstern D, Yahalom-Ronen Y, Tamir H, Achdout H, Stein D, Israeli O, Beth-Din A, Sharon, Melamed S, Weiss S, Israely T, Paran N, Schwartz M, Stern-Ginossar N (2021) The coding capacity of SARS-CoV-2. Nature 589(7840):125–130. https://doi.org/10.1038/s41586-020-2739-1
Fishman PS, Gass JS, Swoveland PT et al (1985) Infection of the basal ganglia by a murine coronavirus. Science 229:877–879. https://doi.org/10.1126/SCIENCE.2992088
Follmer C (2020) Viral infection-induced gut dysbiosis, neuroinflammation, and α-synuclein aggregation: updates and perspectives on COVID-19 and neurodegenerative disorders. ACS Chem Neurosci 11:4012–4016. https://doi.org/10.1021/ACSCHEMNEURO.0C00671
Frediansyah A, Tiwari R, Sharun K et al (2021) Antivirals for COVID-19: a critical review. Clin Epidemiol Glob Health 9:90–98. https://doi.org/10.1016/J.CEGH.2020.07.006
Fyfe I (2020) Aspirin and ibuprofen could lower risk of LRRK2 Parkinson disease. Nat Rev Neurol 16:460. https://doi.org/10.1038/S41582-020-0394-7
Gaskill PJ, Yano HH, Kalpana GV et al (2014) Dopamine receptor activation increases HIV entry into primary human macrophages. PLoS ONE. https://doi.org/10.1371/journal.pone.0108232
Goswami P, Gupta S, Biswas J et al (2016) Endoplasmic reticulum stress instigates the rotenone induced oxidative apoptotic neuronal death: a study in rat brain. Mol Neurobiol 53:5384–5400. https://doi.org/10.1007/s12035-015-9463-0
Grieb P, Świątkiewicz M, Prus K, Rejdak K (2021) Amantadine for COVID-19. J Clin Pharmacol 61:412–413
Guilherme EM, Moreira RDFC, de Oliveira A et al (2021) Respiratory disorders in Parkinson’s disease. J Parkinsons Dis. https://doi.org/10.3233/jpd-212565
Gundersen V (2010) Protein aggregation in Parkinson’s disease. Acta Neurol Scand 122:82–87
Guo Q, Zheng Y, Shi J et al (2020) Immediate psychological distress in quarantined patients with COVID-19 and its association with peripheral inflammation: a mixed-method study. Brain Behav Immun 88:17–27. https://doi.org/10.1016/j.bbi.2020.05.038
Haehner A, Boesveldt S, Berendse HW et al (2009) Prevalence of smell loss in Parkinson’s disease - a multicenter study. Parkinsonism Relat Disord 15:490–494. https://doi.org/10.1016/j.parkreldis.2008.12.005
Haehner A, Hummel T, Reichmann H (2014) A clinical approach towards smell loss in Parkinson’s disease. J Parkinsons Dis 4:189–195
Hawkes CH, del Tredici K, Braak H (2007) Parkinson’s disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 33:599–614
Hirsch EC, Hunot S, Damier P, Faucheux B (1998) Glial cells and inflammation in parkinson's disease: A role in neurodegeneration?. Ann Neurol 44(S1):S115–S120. https://doi.org/10.1002/ana.410440717
Hirsch EC, Standaert DG (2021) Ten unsolved questions about neuroinflammation in Parkinson’s disease. Mov Disord 36:16–24. https://doi.org/10.1002/MDS.28075
Hubsher G, Haider M, Okun MS (2012) Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology 78:1096–1099
Idrees D, Kumar V (2021) SARS-CoV-2 spike protein interactions with amyloidogenic proteins: potential clues to neurodegeneration. Biochem Biophys Res Commun 554:94–98. https://doi.org/10.1016/j.bbrc.2021.03.100
Islam N, Rahman S (2021) Novel pulmonary delivery of antiviral drugs for treating covid-19 in patients with Parkinson’s disease. Curr Drug Deliv. https://doi.org/10.2174/1567201818666210331121803
Izco M, Blesa J, Verona G et al (2020) Glial activation precedes alpha-synuclein pathology in a mouse model of Parkinson’s disease. Neurosci Res. https://doi.org/10.1016/j.neures.2020.11.004
Jenner P, Olanow CW (1996) Oxidative stress and the pathogenesis of Parkinson’s disease. Neurology 47
Jiang T, Sun Q, Chen S (2016) Oxidative stress: a major pathogenesis and potential therapeutic target of antioxidative agents in Parkinson’s disease and Alzheimer’s disease. Prog Neurobiol 147:1–19. https://doi.org/10.1016/J.PNEUROBIO.2016.07.005
Jo T, Yasunaga H, Michihata N et al (2018) Influence of Parkinsonism on outcomes of elderly pneumonia patients. Parkinsonism Relat Disord 54:25–29. https://doi.org/10.1016/J.PARKRELDIS.2018.03.028
Kanberg N, Ashton NJ, Andersson LM et al (2020) Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurology 95:e1754–e1759. https://doi.org/10.1212/WNL.0000000000010111
Kannarkat GT, Boss JM, Tansey MG (2013) The role of innate and adaptive immunity in Parkinson’s disease. J Parkinsons Dis 3:493–514. https://doi.org/10.3233/JPD-130250
Kesarwani P, Murali AK, Al-Khami AA, Mehrotra S (2013) Redox regulation of T-cell function: from molecular mechanisms to significance in human health and disease. Antioxid Redox Signal 18:1497–1534. https://doi.org/10.1089/ARS.2011.4073
Khalefah MM, Khalifah AM (2020) Determining the relationship between SARS-CoV-2 infection, dopamine, and COVID-19 complications. J Taibah Univ Med Sci 15:550–553. https://doi.org/10.1016/j.jtumed.2020.10.006
Labandeira-García JL, Garrido-Gil P, Rodriguez-Pallares J et al (2014) Brain renin-angiotensin system and dopaminergic cell vulnerability. Front Neuroanat. https://doi.org/10.3389/fnana.2014.00067
Labandeira-Garcia JL, Valenzuela R, Costa-Besada MA et al (2021) The intracellular renin-angiotensin system: friend or foe. Some light from the dopaminergic neurons. Prog Neurobiol 199
Landreau F, Galeano P, Caltana LR et al (2012) Effects of two commonly found strains of influenza a virus on developing dopaminergic neurons, in relation to the pathophysiology of schizophrenia. PLoS ONE. https://doi.org/10.1371/journal.pone.0051068
Lang AE, Lozano AM (1998) Parkinson’s disease. First of two parts. N Engl J Med 339:1044–1053. https://doi.org/10.1056/NEJM199810083391506
Lee MA, Prentice WM, Hildreth AJ, Walker RW (2007) Measuring symptom load in Idiopathic Parkinson’s disease. Parkinsonism Relat Disord 13:284–289. https://doi.org/10.1016/J.PARKRELDIS.2006.11.009
Li Q, Haney MS (2020) The role of glia in protein aggregation. Neurobiol Dis 143
Liu SY, Sanchez DJ, Aliyari R et al (2012) Systematic identification of type I and type II interferon-induced antiviral factors. Proc Natl Acad Sci U S A 109:4239–4244. https://doi.org/10.1073/PNAS.1114981109
MacIntosh DJ (1977) Respiratory dysfunction in Parkinson’s disease. Prim Care 4:441–445
Mazza MG, de Lorenzo R, Conte C et al (2020) Anxiety and depression in COVID-19 survivors: Role of inflammatory and clinical predictors. Brain Behav Immun 89:594–600. https://doi.org/10.1016/j.bbi.2020.07.037
McNaught KSP, Olanow CW (2006) Protein aggregation in the pathogenesis of familial and sporadic Parkinson’s disease. Neurobiol Aging 27:530–545
Mehta SH, Pahwa R, Tanner CM et al (2021) Effects of Gocovri (amantadine) extended release capsules on non-motor symptoms in patients with Parkinson’s disease and dyskinesia. Neurol Ther. https://doi.org/10.1007/s40120-021-00246-3
Melenotte C, Silvin A, Goubet AG et al (2020) Immune responses during COVID-19 infection. Oncoimmunology. https://doi.org/10.1080/2162402X.2020.1807836
Merello M, Bhatia KP, Obeso JA (2021) SARS-CoV-2 and the risk of Parkinson’s disease: facts and fantasy. Lancet Neurol 20:94–95. https://doi.org/10.1016/S1474-4422(20)30442-7
Moro-García MA, Mayo JC, Sainz RM, Alonso-Arias R (2018) Influence of inflammation in the process of T lymphocyte differentiation: proliferative, metabolic, and oxidative changes. Front Immunol. https://doi.org/10.3389/FIMMU.2018.00339
Musgrove RE, Helwig M, Bae EJ et al (2019) Oxidative stress in vagal neurons promotes parkinsonian pathology and intercellular α-synuclein transfer. J Clin Investig 129:3738–3753. https://doi.org/10.1172/JCI127330
Nataf S (2020) An alteration of the dopamine synthetic pathway is possibly involved in the pathophysiology of COVID-19. J Med Virol 92:1743–1744
Nicolini H (2020) Depression and anxiety during COVID-19 pandemic. Cir Cir (English Edition) 88:542–547
Padda I, Khehra N, Jaferi U, Parmar MS (2020) The neurological complexities and prognosis of COVID-19. SN Compr Clin Med 2:2025–2036. https://doi.org/10.1007/S42399-020-00527-2/FIGURES/4
Pairo-Castineira E, Clohisey S, Klaric L et al (2021) Genetic mechanisms of critical illness in COVID-19. Nature 591:92–98. https://doi.org/10.1038/S41586-020-03065-Y
Pennington S, Snell K, Lee M, Walker R (2010) The cause of death in idiopathic Parkinson’s disease. Parkinsonism Relat Disord 16:434–437. https://doi.org/10.1016/J.PARKRELDIS.2010.04.010
Pérez-Cano HJ, Moreno-Murguía MB, Morales-López O et al (2020) Anxiety, depression, and stress in response to the coronavirus disease-19 pandemic. Cir Cir (English Edition) 88:562–568. https://doi.org/10.24875/CIRU.20000561
Plusa T (2021) Przeciwzapalne działanie amantadyny i memantyny w zakażeniu SARS-CoV-2. Pol Merkur Lekarski 49:67–70
Polatli M, Akyol A, Çilda O, Bayülkem K (2001) Pulmonary function tests in Parkinson’s disease. Eur J Neurol 8:341–345. https://doi.org/10.1046/J.1468-1331.2001.00253.X
Rethinavel HS, Ravichandran S, Radhakrishnan RK, Kandasamy M (2021) COVID-19 and Parkinson’s disease: Defects in neurogenesis as the potential cause of olfactory system impairments and anosmia. J Chem Neuroanat 115:101965. https://doi.org/10.1016/j.jchemneu.2021.101965
Rfaki A, Touil N, Hemlali M et al (2021) Complete genome sequence of a SARS-CoV-2 strain sampled in Morocco in May 2020, obtained using sanger sequencing. Microbiol Resour Announc. https://doi.org/10.1128/MRA.00387-21
Rhea EM, Logsdon AF, Hansen KM et al (2021) The S1 protein of SARS-CoV-2 crosses the blood-brain barrier in mice. Nat Neurosci 24:368–378. https://doi.org/10.1038/S41593-020-00771-8
Rice JE, Antic R, Thompson PD (2002) Disordered respiration as a levodopa-induced dyskinesia in Parkinson’s disease. Mov Disord 17:524–527. https://doi.org/10.1002/mds.10072
Schonhoff AM, Williams GP, Wallen ZD et al (2020) Innate and adaptive immune responses in Parkinson’s disease. Prog Brain Res 252:169–216. https://doi.org/10.1016/BS.PBR.2019.10.006
Schrag A, Taddei RN (2017) Depression and anxiety in Parkinson’s disease. In: International Review of Neurobiology. Academic Press Inc., pp 623–655
Semerdzhiev SA, Fakhree MAA, Segers-Nolten I et al (2021) Interactions between SARS-CoV-2 N-protein and α-synuclein accelerate amyloid formation. bioRxiv. https://doi.org/10.1101/2021.04.12.439549
Serebrovskaya T, Karaban I, Mankovskaya I et al (1998) Hypoxic ventilatory responses and gas exchange in patients with Parkinson’s disease. Respiration 65:28–33. https://doi.org/10.1159/000029224
Shader RI (2020) COVID-19 and depression. Clin Ther 42:962–963. https://doi.org/10.1016/j.clinthera.2020.04.010
Shaskan EG, Oreland L, Wadell G (1984) Dopamine receptors and monoamine oxidase as virion receptors. Perspect Biol Med 27:239–250. https://doi.org/10.1353/pbm.1984.0032
Shill H, Stacy M (2002) Respiratory complications of Parkinson’s disease. Semin Respir Crit Care Med 23:261–265. https://doi.org/10.1055/S-2002-33034
Shults CW (2005) Antioxidants as therapy for Parkinson’s disease. Antioxid Redox Signal 7:694–700. https://doi.org/10.1089/ARS.2005.7.694
Simanjuntak Y, Liang JJ, Lee YL, Lin YL (2017) Japanese encephalitis virus exploits dopamine D2 receptor-phospholipase C to target dopaminergic human neuronal cells. Front Microbiol. https://doi.org/10.3389/fmicb.2017.00651
Singh S, Joshi N (2017) Astrocytes: inexplicable cells in neurodegeneration. Int J Neurosci 127:204–209
Smieszek SP, Przychodzen BP, Polymeropoulos MH (2020) Amantadine disrupts lysosomal gene expression: a hypothesis for COVID19 treatment. Int J Antimicrob Agents. https://doi.org/10.1016/j.ijantimicag.2020.106004
Smith JL, Stein DA, Shum D et al (2014) Inhibition of dengue virus replication by a class of small-molecule compounds that antagonize dopamine receptor D4 and downstream mitogen-activated protein kinase signaling. J Virol 88:5533–5542. https://doi.org/10.1128/jvi.00365-14
Song E, Zhang C, Israelow B et al (2021) Neuroinvasion of SARS-CoV-2 in human and mouse brain. J Exp Med. https://doi.org/10.1084/JEM.20202135
Spuntarelli V, Luciani M, Bentivegna E et al (2020) COVID-19: is it just a lung disease? A case-based review. SN Compr Clin Med 2:1401–1406. https://doi.org/10.1007/S42399-020-00418-6
Stolzenberg E, Berry D, Yang D et al (2017) A role for neuronal alpha-synuclein in gastrointestinal immunity. J Innate Immun 9:456–463. https://doi.org/10.1159/000477990
Tansey MG, Goldberg MS (2010) Neuroinflammation in Parkinson’s disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 37:510–518. https://doi.org/10.1016/J.NBD.2009.11.004
Tavassoly O, Safavi F, Tavassoly I (2020) Seeding brain protein aggregation by SARS-CoV-2 as a possible long-term complication of COVID-19 infection. ACS Chem Neurosci 11:3704–3706
Torsney KM, Forsyth D (2017) Respiratory dysfunction in Parkinson’s disease. J R Coll Physicians Edinb 47:35–39. https://doi.org/10.4997/JrcPe.2017.108
Troisi J, Venutolo G, Tanyà MP et al (2021) COVID-19 and the gastrointestinal tract: source of infection or merely a target of the inflammatory process following SARS-CoV-2 infection? World J Gastroenterol 27:1406–1418
Ulusoy A, Rusconi R, Pérez-Revuelta BI et al (2013) Caudo-rostral brain spreading of α-synuclein through vagal connections. EMBO Mol Med 5:1119–1127. https://doi.org/10.1002/emmm.201302475
Wang X, Michaelis EK (2010) Selective neuronal vulnerability to oxidative stress in the brain. Front Aging Neurosci 2
WHO Solidarity Trial Consortium, Pan H, Peto R, Henao-Restrepo AM, Preziosi MP,Sathiyamoorthy V, Abdool Karim Q, Alejandria MM, Hernández García C, Kieny MP,Malekzadeh R, Murthy S, Reddy KS, Roses Periago M, Abi Hanna P, Ader F, Al-Bader AM,Alhasawi A, Allum E, Alotaibi A, Alvarez-Moreno CA, Appadoo S, Asiri A, Aukrust P, Barratt-Due A, Bellani S, Branca M, Cappel-Porter HBC, Cerrato N, Chow TS, Como N, Eustace J,García PJ, Godbole S, Gotuzzo E, Griskevicius L, Hamra R, Hassan M, Hassany M, Hutton D,Irmansyah I, Jancoriene L, Kirwan J, Kumar S, Lennon P, Lopardo G, Lydon P, Magrini N,Maguire T, Manevska S, Manuel O, McGinty S, Medina MT, Mesa Rubio ML, Miranda-MontoyaMC, Nel J, Nunes EP, Perola M, Portolés A, Rasmin MR, Raza A, Rees H, Reges PPS, RogersCA, Salami K, Salvadori MI, Sinani N, Sterne JAC, Stevanovikj M, Tacconelli E, Tikkinen KAO,Trelle S, Zaid H, Røttingen JA, Swaminathan S. (2021) Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results. N Engl J Med 384(6):497–511. https://doi.org/10.1056/NEJMoa2023184. Epub 2020 Dec 2. PMID: 33264556; PMCID: PMC7727327
Yang DM, Lin FC, Tsai PH et al (2021a) Pandemic analysis of infection and death correlated with genomic open reading frame 10 mutation in severe acute respiratory syndrome coronavirus 2 victims. J Chin Med Assoc 84:478–484. https://doi.org/10.1097/JCMA.0000000000000542
Yang Y, Huang W, Fan Y, Chen GQ (2021b) Gastrointestinal microenvironment and the gut-lung axis in the immune responses of severe COVID-19. Front Mol Biosci 8
Yu C, Kang L, Chen J, Zang N (2020) Evaluation of safety, efficacy, tolerability, and treatment-related outcomes of type I interferons for human coronaviruses (HCoVs) infection in clinical practice: an updated critical systematic review and meta-analysis. Int Immunopharmacol. https://doi.org/10.1016/j.intimp.2020.106740
Zhang L, Zhou L, Bao L et al (2021) SARS-CoV-2 crosses the blood-brain barrier accompanied with basement membrane disruption without tight junctions alteration. Signal Transduct Target Ther. https://doi.org/10.1038/S41392-021-00719-9
Zhou L, Miranda-Saksena M, Saksena NK (2013) Viruses and neurodegeneration. Virol J 10
Funding
The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article. We would like to acknowledge the Indian Council of Medical Research for financial support (2016–0264/CMB/ADHOC-BMS).
Author information
Authors and Affiliations
Contributions
Shubhangini Tiwari contributed in preparation of the draft manuscript. Neelam Yadav edited the manuscript. Sarika Singh conceptualized, reviewed, and edited the manuscript.
Corresponding author
Ethics declarations
Ethics Approval and Consent to Participate
Not applicable.
Consent for Publication
All authors read and approved the final manuscript.
Competing Interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Tiwari, S., Yadav, N. & Singh, S. COVID-19 and Parkinson’s Disease: Possible Links in Pathology and Therapeutics. Neurotox Res 40, 1586–1596 (2022). https://doi.org/10.1007/s12640-022-00540-4
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12640-022-00540-4